1. What It Is (Mechanism of Action)
GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) chelated with copper (Cu2+). Discovered in human plasma in 1973 by Dr. Loren Pickart, it regulates gene expression involved in collagen synthesis, elastin formation, anti-inflammatory cytokine modulation, and antioxidant defenses.
2. Clinical Indications Under Study
Topical skin remodeling, wound healing, hair follicle enlargement, cosmetic anti-aging, and pulmonary fibrosis attenuation.
3. FDA Approval & Regulatory Status
Cosmetic Ingredient (Not FDA Approved as an Injectable Drug)
4. Human Clinical Evidence Summary
5. Known Risks, Side Effects & Boxed Warnings
Topical formulations are generally well-tolerated with low irritancy. Systemic/injectable use carries risks of systemic copper toxicity (Wilson's disease exacerbation), local injection site pain, tissue necrosis, and severe photolytic copper dissociation if stored improperly.
6. Legal, Prescription & Compounding Status
Widely legal and regulated as a cosmetic ingredient in topical serums and creams. Unapproved for injectable drug compounding under FDA 503A rules.
7. Why Gray-Market "Research Chemical" Versions Are Risky
Get Breaking GHK-Cu Clinical Trial Alerts
Receive verified FDA dockets, Phase 3 readouts, and independent HPLC lab audits directly from our medical journalism desk.
8. Questions to Ask a Licensed Clinician
If you are discussing this compound with your doctor or healthcare provider, consider bringing these evidence-based questions:
- Q1: What is the safety profile of topical GHK-Cu formulations compared to off-label injectable preparations?
- Q2: Are there interactions between copper peptide skincare and active retinoids or ascorbic acid?
9. Primary Peer-Reviewed Sources & Citations
- [1] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PubMed / Source →
- [2] Badenhorst T, et al. Delivery of the copper tripeptide (GHK-Cu) through human skin. Drug Dev Ind Pharm. 2016;42(8):1243-1250. PubMed / Source →